8-K: Niagen Bioscience Soars with 30% Sales Growth in 2025

Niagen Bioscience, Inc. reported a robust 30% year-over-year net sales increase to $129.4 million and a 103% net income surge to $17.4 million for fiscal year 2025, alongside a positive 2026 outlook.

Summary

• Full year 2025 net sales increased 30% year-over-year to $129.4 million.
• Full year 2025 net income increased 103% year-over-year to $17.4 million, or $0.22 basic EPS.
• Full year 2025 Adjusted EBITDA increased 139% year-over-year to $20.4 million.
• Gross margin improved 250 basis points year-over-year to 64.3% in 2025.
• Cash and cash equivalents totaled $64.8 million at December 31, 2025, compared to $44.7 million at December 31, 2024, with no outstanding borrowings.
• Fourth quarter 2025 net sales increased 16% to $33.8 million, with Tru Niagen sales up 21%.
• Fourth quarter 2025 net income was $4.1 million, compared to $7.2 million in the prior year quarter, which benefited from significant one-time reversals and recoveries.
• In February 2026, the company sold its analytical reference standards and services operating segment for approximately $6.0 million.
• In January 2026, a partnership with Truemed was announced, enabling HSA/FSA funds for Tru Niagen purchases.
• In December 2025, the core nicotinamide riboside (NR) patent portfolio was acquired from Queens University Belfast.
• In November 2025, Tru Niagen Beauty was launched, expanding into the beauty and nutricosmetics category.
• In November 2025, positive results from a clinical trial evaluating Niagen supplementation in individuals with long COVID were announced.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, demonstrating strong financial growth, strategic execution, and a solid cash position, despite a slight dip in Q4 net income due to comparative factors.

Positives

• Full year 2025 net sales grew 30% to $129.4 million, meeting or exceeding the company's latest financial outlook.
• Full year 2025 net income increased 103% to $17.4 million, demonstrating strong profitability growth.
• Full year 2025 Adjusted EBITDA surged 139% to $20.4 million.
• Gross margin improved by 250 basis points to 64.3% for the full year 2025, driven by favorable product mix and improved utilization.
• Ended 2025 with a strong cash position of $64.8 million and no outstanding borrowings, up from $44.7 million in 2024.
• Generated positive operating cash flow of $13.5 million in 2025.
• Successfully sold the analytical reference standards segment for approximately $6.0 million in February 2026, streamlining operations.
• Acquired the core NR patent portfolio from Queens University Belfast, enhancing control over foundational intellectual property.
• Launched Tru Niagen Beauty, expanding the consumer portfolio into a new, high-growth market segment.
• Partnered with Truemed to allow HSA/FSA purchases of Tru Niagen, increasing payment flexibility and accessibility for eligible customers.
• Announced positive clinical trial results for Niagen supplementation in individuals with long COVID, supporting continued scientific evaluation.
• Selling and marketing expense improved 220 basis points as a percentage of net sales to 27.4%, reflecting increased operating leverage.

Negatives

• Fourth quarter 2025 net income decreased to $4.1 million from $7.2 million in the prior year quarter, primarily due to elevated operating expenses in the current year quarter, as the prior year quarter included benefits that exceeded the $2.0 million gain recognized in the current quarter.
• General and administrative (G&A) expense increased significantly in Q4 2025 and FY 2025, reflecting the absence of prior year's one-time reversals and recoveries, as well as higher employee-related and share-based compensation expenses.

Risks

• Relationships with major customers could impact sales and revenue.
• A decline in general economic conditions nationally and internationally may reduce demand for products.
• The market size and acceptance of vitamin, mineral, dietary supplement, and intravenous markets may not grow as anticipated.
• Decreased demand for products and services could negatively affect financial performance.
• Market acceptance of products is not guaranteed.
• The ability to protect intellectual property rights is crucial for competitive advantage.
• Litigation or infringement actions brought against the company could incur significant costs and impact operations.
• Competition from other providers and products poses a threat to market share.
• Risks inherent in product development, including failure to meet regulatory standards or market needs.
• The ability to successfully develop a pharmaceutical business is uncertain.
• Inability to raise capital could hinder continuing operations or new product development.
• Changes in government regulation or regulatory priorities could impact product development and commercialization.
• The ability to complete customer transactions and capital raising transactions may be challenging.
• Inflationary conditions and adverse economic conditions could increase costs and reduce consumer spending.
• The company has a history of operating losses, which may continue.
• The growth and profitability of product sales are not guaranteed.
• The ability to maintain and grow sales, marketing, and distribution capabilities is essential for expansion.
• Changing consumer perceptions of products could negatively affect brand reputation and sales.
• Reliance on a single or limited number of third-party suppliers creates supply chain risks.
• Risks associated with conducting business in China, including regulatory and economic uncertainties.
• Unanticipated developments related to securing adequate quantities of pharmaceutical-grade Niagen in a timely manner.
• The ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities.
• The ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B Category 1 list.
• The ability to maintain and enforce existing intellectual property and obtain new patents.
• Uncertainty whether the potential benefits of NRC can be further supported by scientific evidence.
• Further research and development and clinical trials may be unsuccessful or insufficient to meet regulatory standards.
• The ability to enroll sufficient numbers of subjects in clinical trials is critical for research progress.
• Determinations made by the FDA and other governmental authorities could impact product approvals and market access.
• Mislabeling or other misleading marketing practices by competitors could harm the company's market position.
• Economic and market instability, including tariffs or trade conflicts, could adversely affect business operations.

Future Outlook

For 2026, Niagen Bioscience expects net sales growth of 10-15% year-over-year, excluding revenue from the recently sold analytical reference standards segment, driven primarily by e-commerce business and new strategic partnerships. Gross margin is projected for slight improvement year-over-year due to improvements in inventory cost and product mix. Sales & marketing expenses are expected to increase in absolute dollars but remain stable as a percentage of sales, driven by optimized investments. Research & development and General & administrative expenses are also projected to increase in absolute dollars to support pharmaceutical development, external research initiatives, infrastructure investments, and legal expenses.

Management Comments

• Niagen Bioscience delivered net sales of $33.8 million for the fourth quarter of 2025, representing a 16% increase compared to the prior year period, and generated net income of $4.1 million.
• For the full year, net sales were $129.4 million, an increase of 30% year-over-year, with net income of $17.4 million and operating cash flow of $13.5 million.
• We ended the year with $64.8 million in cash, providing a strong financial foundation to support continued investment in our strategic priorities and growth.

Industry Context

StockSavvy.ai notes that Niagen Bioscience's strong performance in 2025, particularly the significant growth in Tru Niagen sales and strategic moves like the patent acquisition and new product launches, positions it favorably within the expanding healthy aging and nutricosmetics markets. The focus on NAD+ precursors aligns with a growing consumer interest in longevity and cellular health, a trend that continues to drive innovation and investment in the bioscience and dietary supplement sectors.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry benchmarking against global standards.

Legal Proceedings

• The prior year (2024) included a $1.3 million recovery of credit losses related to the Elysium Health legal settlement.
• 2025 included a $2.0 million gain recognized related to the settlement of royalty obligations under an agreement with Queens University Belfast.

Stakeholder Impact

• Shareholders are positively impacted by strong financial performance, increased net income and EPS, strategic intellectual property acquisition, and a solid cash position.
• Customers benefit from expanded product offerings (Tru Niagen Beauty), increased payment flexibility (Truemed partnership), and continued scientific validation of products.
• Employees may benefit from higher employee-related and share-based compensation expenses.
• Suppliers may see increased demand due to higher inventory levels to support business growth.

Next Steps

• Continued investment in strategic priorities and growth.
• Continued scientific evaluation of NAD+ restoration in populations experiencing prolonged post-viral symptoms.
• Further research and development to support new product development and innovation.
• Targeted investments to support the launch of new verticals.
• Investor conference call on March 4, 2026, to discuss results and provide a general business update.

Key Dates

Recommendation

The company delivered exceptional full-year 2025 financial results, significantly exceeding its own guidance for net sales and demonstrating robust growth in net income and Adjusted EBITDA. The strong cash position, strategic intellectual property acquisition, expansion into new product categories, and positive 2026 outlook indicate strong operational momentum and future growth potential. While Q4 net income saw a comparative decline, it was largely due to one-time benefits in the prior year, and the underlying operational performance remains strong. These factors collectively present a compelling investment case.

Keywords

Niagen Bioscience, NAGE, NAD+, Nicotinamide Riboside, Tru Niagen, Dietary Supplements, Healthy Aging, Financial Results, Earnings, Bioscience, Nutraceuticals, Intellectual Property, Clinical Trials, Consumer Health, Biotechnology